All In Biotech

Drug Trial Radar · NCT06321913

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Phase II Study to Evaluate the Safety, Tolerability and Efficacy of IBI343 Combined With Sintilimab in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

25

Planned (sponsor's estimate)

Start

Mar 15, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Harbin Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Innovent Biologics (Suzhou) Co. Ltd.
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial\] is toevaluate the safety, tolerability and efficacy of IBI343 combined with sintilimab in the treatment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma. The main aim is to evaluate the efficacy and safety of IBI343 combination treatment in subjects with advanced gastric/gastroesophageal junction adenocarcinoma.The secondary aim is to evaluate other efficacy endpoints in subjects with IBI343 combination therapy for advanced gastric/gastroesophageal junction adenocarcinoma.The exploratory purpose is to evaluate the correlation between CLDN18.2 expression levels in tumor tissues and the efficacy of IBI343 combination therapy. Participants will be asked to enroll about 3-12 patients in the safety introduction period.,and about 25 patients are planned to be enrolled in the POC phase.

Conditions

  • Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

  • IBI343 combined with IBI308Drug

    IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 24 months
  2. AETime frame: 24 months
  3. Treatment-Emergent Adverse Event (TEAE)Time frame: 24 months
  4. Adverse Event of Special Interest (AESI)Time frame: 24 months
  5. Serious Adverse Event (SAE)Time frame: 24 months
  6. laboratory examinationsTime frame: 24 months
  7. physical examinationsTime frame: 24 months
  8. vital signsTime frame: 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.